Um estudo de eficácia e segurança de ALZ-801 em indivíduos com DA precoce APOE4/4 (APOLLOE4)
Um estudo de fase 3, multicêntrico, randomizado, duplo-cego, controlado por placebo da eficácia, segurança e efeitos do biomarcador de ALZ-801 em indivíduos com doença de Alzheimer precoce e genótipo APOE4/4
This study is being conducted to evaluate the safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 genotype. This is a double-blind, randomized trial with one dose of ALZ-801 compared to placebo.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is a multi-center, double-blind study that will evaluate 265 mg twice daily (BID) of ALZ-801, an oral tablet, over 78 weeks as a treatment for subjects (50-80 years old) with Early AD who are homozygous for the ε4 allele of the apolipoprotein gene (APOE4 homozygous or APOE4/4). The primary efficacy outcome assessment is a measure of cognition (ADAS-cog 13). Additional measures of global and functional impairments will also be assessed. Imaging and soluble biomarkers of AD and neurodegeneration will be measured and a sub-study to evaluate cerebrospinal fluid (CSF) biomarkers is also included.
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Fase 3
Contactos e Locais
Locais de estudo
-
-
-
Aachen, Alemanha, 52074
- University Hospital RWTH Aachen Neurological Study Center
-
München, Alemanha, 80336
- Klinikum der Universitaet Muenchen Innenstadt
-
Tübingen, Alemanha, 72076
- Universitätsklinik fuer Psychiatrie und Psychotherapie
-
Westerstede, Alemanha, 26655
- Studienzentrum Nord-West
-
-
-
-
British Columbia
-
Kelowna, British Columbia, Canadá, V1Y 1Z9
- OCT Research ULC (dba Okanagan Clinical Trials)
-
-
Nova Scotia
-
Halifax, Nova Scotia, Canadá, B3S 1N2
- Centricity Research
-
New Minas, Nova Scotia, Canadá, B4N 3R7
- Centricity Research
-
-
Ontario
-
Ottawa, Ontario, Canadá, K1Z 1G3
- Recherches Neuro-Hippocampe Inc., d/b/a Ottawa Memory Clinic
-
Peterborough, Ontario, Canadá, K9H 2P4
- Kawartha Centre - Redefining Healthy Aging
-
Toronto, Ontario, Canadá, M3B 2S7
- Toronto Memory Program
-
-
Quebec
-
Gatineau, Quebec, Canadá, J8T 8J1
- Recherches Neuro-Hippocampe Inc. d/b/a Clinique de la Mémoire de l'Outaouais
-
-
-
-
-
Barcelona, Espanha, 08028
- Fundacia ACE - Institut Catala de Neurociencies Aplicadas
-
Madrid, Espanha, 28040
- Hospital Clinico San Carlos
-
Madrid, Espanha, 28027
- Clinica Universidad de Navarra
-
Pamplona, Espanha, 31008
- Clinica Universidad de Navarra
-
Terrassa, Espanha, 08221
- Hospital Universitari MutuaTerrassa
-
Valencia, Espanha, 46017
- Centro Hospital Universitario Dr. Preset
-
-
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85004
- Xenoscience
-
Scottsdale, Arizona, Estados Unidos, 85297
- CCT Research
-
Sun City, Arizona, Estados Unidos, 85351
- Banner Sun Health Research Institute
-
-
California
-
Costa Mesa, California, Estados Unidos, 92626
- ATP Clinical Research
-
Irvine, California, Estados Unidos, 92780
- Tilda Research
-
La Jolla, California, Estados Unidos, 92037
- UCSD Shiley-Marcos Alzheimer's Disease Research Center
-
Lomita, California, Estados Unidos, 90717
- Torrance Clinical Research Institute
-
Long Beach, California, Estados Unidos, 90806
- Collaborative NeuroScience Network LLC
-
Palo Alto, California, Estados Unidos, 94304
- Stanford University
-
Pasadena, California, Estados Unidos, 91105
- SC3 Research Group
-
Sacramento, California, Estados Unidos, 95816
- Sutter Health
-
-
Florida
-
Atlantis, Florida, Estados Unidos, 33462
- JEM Research Institute, Headlands Site
-
Bradenton, Florida, Estados Unidos, 34205
- Bradenton Research Center
-
Hialeah, Florida, Estados Unidos, 33016
- Galiz Research
-
Jupiter, Florida, Estados Unidos, 33458
- Alphab Global Research
-
Lady Lake, Florida, Estados Unidos, 32159
- Charter Research
-
Maitland, Florida, Estados Unidos, 32751
- K2 Medical Research, LLC
-
Miami, Florida, Estados Unidos, 33137
- Miami Jewish Health
-
Miami, Florida, Estados Unidos, 33144
- Y & L Advance Health Care, Inc /DBA Elite Clinical Research
-
Miami Beach, Florida, Estados Unidos, 33140
- Mount Sinai Medical Center
-
Naples, Florida, Estados Unidos, 34105
- Aqualane Clinical Research
-
Orlando, Florida, Estados Unidos, 32819
- Headlands Research Orlando
-
Orlando, Florida, Estados Unidos, 32803
- Charter Research
-
Palm Beach Gardens, Florida, Estados Unidos, 33410
- Advanced Research Consultants
-
Pompano Beach, Florida, Estados Unidos, 33064
- Quantum CNS Clinical Research
-
Port Orange, Florida, Estados Unidos, 32127
- Progressive Medical Research
-
Stuart, Florida, Estados Unidos, 34997
- ALZ Research and Treatment Center (A.R.T.C.)
-
Wellington, Florida, Estados Unidos, 33414
- ALZ Research and Treatment Center (A.R.T.C.)
-
West Palm Beach, Florida, Estados Unidos, 33407
- Premiere Research Institute
-
-
Georgia
-
Columbus, Georgia, Estados Unidos, 31909
- Columbus Memory Center
-
Decatur, Georgia, Estados Unidos, 30030
- Sandhill Research, LLC
-
-
Indiana
-
Fort Wayne, Indiana, Estados Unidos, 46804
- Fort Wayne Neurological Center
-
-
Louisiana
-
Shreveport, Louisiana, Estados Unidos, 71103
- Louisiana State University Health Sciences Center (LSUHSC)
-
-
Massachusetts
-
Plymouth, Massachusetts, Estados Unidos, 02360
- Headlands Research Eastern MA
-
-
Nevada
-
Las Vegas, Nevada, Estados Unidos, 89106
- WR-CRCN
-
-
New Jersey
-
Toms River, New Jersey, Estados Unidos, 08755
- Advanced Memory Research Center
-
-
New York
-
Albany, New York, Estados Unidos, 12208
- Neurological Associates of Albany
-
New York, New York, Estados Unidos, 10016
- NYU Alzheimer's Disease Research Center
-
Orangeburg, New York, Estados Unidos, 10962
- Kline Institute for Psychiatric Research
-
Rochester, New York, Estados Unidos, 14620
- University of Rochester Medical Center
-
Staten Island, New York, Estados Unidos, 10312
- Richmond Behavioral Associates
-
-
North Carolina
-
Greensboro, North Carolina, Estados Unidos, 27410
- Triad Clinical Trials
-
Matthews, North Carolina, Estados Unidos, 28105
- AMC Research
-
-
Ohio
-
Canton, Ohio, Estados Unidos, 44718
- NeuroScience Research Center
-
Dayton, Ohio, Estados Unidos, 45459
- Neurology Diagnostics, Inc.
-
-
Oklahoma
-
Oklahoma City, Oklahoma, Estados Unidos, 73106
- IPS Research
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97225
- Center for Cognitive Health
-
-
Pennsylvania
-
Abington, Pennsylvania, Estados Unidos, 19001
- Abington Neurological Associates
-
Allentown, Pennsylvania, Estados Unidos, 18104
- Lehigh Center for Clinical Research
-
-
Rhode Island
-
East Providence, Rhode Island, Estados Unidos, 02914
- Rhode Island Mood & Memory Research Institute
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37212
- Vanderbilt Center for Cognitive Medicine
-
-
Texas
-
Houston, Texas, Estados Unidos, 77054
- UT Health Science Center at Houston
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Re:Cognition Health
-
-
Washington
-
Bellevue, Washington, Estados Unidos, 98007
- Northwest Clinical Research Center
-
-
Wisconsin
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Medical College of Wisconsin
-
-
-
-
-
Marseille, França, 13385
- Centre Hospitalier Universitaire de Marseille - Hôpital de la Timone
-
Montpellier, França, 43431
- Hopital Gui de Chauliac - CHRU de Montpellier
-
Paris, França, 75475
- Hopital Lariboisiere - Fernand-Widal - AP-HP
-
Rouen, França, 76031
- Centre Hospitalier Universitaire (CHU) Hopitaux de Rouen
-
Strasbourg, França, 67200
- Hopitaux Universitaires de Strasbourg Centre d'Investigation Clinique
-
Toulouse, França, 31059
- Centre de Recherche Clinique du Gerontopole - CHU Toulouse
-
Villeurbanne, França, 69100
- Centre de Recherche-Hopital Geriatrique de Charpennes
-
-
-
-
-
's-Hertogenbosch, Holanda, 5223 LA
- Brain Research Center Den Bosch
-
Amsterdam, Holanda, 1081 GN
- Brain Research Center Amsterdam
-
Zwolle, Holanda, 8025 AZ
- Brain Research Center Zwolle
-
-
-
-
-
Reykjavik, Islândia, 101
- Memory Clinic, Landspitali University Hospital
-
-
-
-
-
Bristol, Reino Unido, BS32 4SY
- Re:Cognition Health Ltd Bristol
-
London, Reino Unido, EC2Y 8EA
- St. Pancras Clinical Research
-
Winchester, Reino Unido, SO21 1HU
- Re-Cognition Health Ltd Winchester
-
-
Devon
-
Plymouth, Devon, Reino Unido, PL6 8BT
- Re-Cognition Health Ltd Plymouth
-
-
Greater London
-
London, Greater London, Reino Unido, W1G 9JF
- Re-Cognition Health Ltd London
-
-
North Lanarkshire
-
Motherwell, North Lanarkshire, Reino Unido, ML1 4UF
- NeuroClin Glasgow Ltd
-
-
Surrey
-
Guildford, Surrey, Reino Unido, GU2 7YD
- Re-Cognition Health Ltd Guildford
-
-
West Midlands
-
Birmingham, West Midlands, Reino Unido, B16 8LT
- Re-Cognition Health Ltd Birmingham
-
-
-
-
-
Brno, Tcheca, 656 91
- Fakultní nemocnice u sv. Anny v Brně (St. Anne's University Hospital)
-
Brno, Tcheca, 602 00
- Medica 111, Spol. s r.o. - Neurologicka a Rehabilitacni Ambulance Brno, Centralni Pracoviste v Brne
-
Prague, Tcheca, 160 00
- Neuropsychiatrie s.r.o.
-
Rychnov nad Kněžnou, Tcheca, 51601
- Vestra Clinics - Dedicated Research Clinics
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Clinical diagnosis of MCI or Mild Dementia due to AD consistent with the National Institute on Aging-Alzheimer's Association (NIA-AA) Working Group Criteria.
- Homozygous for the ε4 allele of the apolipoprotein E gene (APOE4/4).
- MMSE score at Screening of 22 to 30 (inclusive).
- CDR - Global score of 0.5 or 1 and CDR Memory Box Score of ≥ 0.5.
- RBANS delayed memory index score ≤ 85.
- Evidence of progressive memory loss over the last 12 months per investigator assessment
Exclusion Criteria:
- Brain magnetic resonance imaging (MRI) indicative of significant abnormality per central reader, other than AD related atrophy. Computed tomography (CT) scan acceptable for subjects who cannot undergo MRI.
- Diagnosis of neurodegenerative disorder other than AD.
- Diagnosis of major depressive disorder (MDD) within one year prior to screening.
- Currently taking memantine or has taken memantine within 12 weeks prior to the Baseline Visit.
- History of suicidal behavior within one year prior to screening or has ongoing suicidal ideation.
- History of seizures, excluding febrile seizures of childhood or a single distant seizure (> 5 years).
- Medically confirmed history of recent cerebral infarct or transient ischemic attack within one year prior to screening.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Quadruplicar
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: ALZ-801
ALZ-801 265 mg BID tablet orally. Subjects will receive placebo in the morning and one tablet of ALZ-801 265 mg tablet in the evening during the first two weeks of the study; thereafter, they will receive a 265 mg tablet twice daily (BID). |
ALZ-801 tablet 265 mg once daily in the evening for the first 2 weeks, then ALZ-801 tablet 265 mg BID
Outros nomes:
Placebo tablet BID |
|
Comparador de Placebo: Placebo
Subjects in the placebo treatment arm will receive placebo tablets BID throughout the study |
Placebo tablet BID |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Primary Cognitive Efficacy Endpoint (ADAS-Cog13)
Prazo: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-Cog13) scores. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Incidence, Nature, and Severity of Treatment Emergent Adverse Events (TEAE)
Prazo: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Safety and tolerability as measured by incidence, nature and severity of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs leading to withdrawal. |
Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Key Secondary Endpoint (A-IADL-W)
Prazo: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
Key Secondary Endpoint (CDR-SB)
Prazo: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Functional Assessment (DAD)
Prazo: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Global Cognition Assessment (MMSE)
Prazo: Baseline to Week 78
|
Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills. |
Baseline to Week 78
|
Outras medidas de resultado
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Imaging Biomarker Endpoint (Hippocampal Volume)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Cortical Thickness [Whole Cortex])
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Cortical Thickness [Mayo Index])
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Whole Brain Volume)
Prazo: Baseline to Week 78
|
Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint (Ventricular Volume)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint - DTI in Grey Matter Mean Diffusivity - Bilateral Caudate
Prazo: Baseline to Week 78
|
Change from baseline in Grey Matter Mean Diffusivity (Bilateral Caudate) as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint - DTI in White Matter Mean Diffusivity (Bilateral Fornix)
Prazo: Baseline to Week 78
|
Change from baseline in Bilateral Fornix White Matter Mean Diffusivity as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). The mean diffusivity (MD) is the average of the three main diffusion values (eigenvalues) obtained from the diffusion tensor imaging (DTI). It is expressed as mm2/s. This unit quantifies the average rate of water diffusion across all directions within a tissue, providing an overall measure of tissue microstructural properties. Lower MD value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as lower mean diffusivity compared with the placebo group. |
Baseline to Week 78
|
|
Imaging Biomarker Endpoint - White Matter Fractional Anisotropy (Bilateral Fornix)
Prazo: Baseline to Week 78
|
Change from baseline in Bilateral Fornix White Matter Fractional Anisotropy as measured by Diffusion Tensor Imaging - Magnetic Resonance Imaging (DTI-MRI). Fractional anisotropy (FA) is a unitless, scalar value that measures the degree of anisotropic (directional) water diffusion within a voxel, ranging from 0 to 1. A value of 0 indicates perfectly isotropic (equal in all directions) diffusion, while a value of 1 indicates perfectly anisotropic (directional) diffusion. Higher FA value suggests better maintenance of microstructural integrity of a given brain tissue. Positive treatment effects of ALZ-801 on DTI would present as higher FA in the ALZ-801 group compared with the placebo group. |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - MCI Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Mild Alzheimer's Disease(Mild AD) Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
A-IADL-W - MCI Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
A-IADL-W - Mild AD Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
CDR-SB - MCI Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
CDR-SB - Mild AD Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - MCI Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - Mild AD Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Global Cognition Assessment (MMSE) - MCI Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills. |
Baseline to Week 78
|
|
Global Cognition Assessment (MMSE) - Mild AD Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Mini-Mental State Examination (MMSE) score. The MMSE is a measure of global cognition that is widely used for clinical staging of Alzheimer's Disease. It consists of 11 domains items for a score range of 0-30 to assess general cognitive function. Higher score on MMSE means better cognitive skills. |
Baseline to Week 78
|
|
Hippocampal Volume (MCI Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration. |
Baseline to Week 78
|
|
Hippocampal Volume (Mild AD Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) hippocampal volume (HV) (uL) as measured by Magnetic Resonance Imaging (MRI). HV atrophy is an early event in AD patients, especially in APOE4/4 homozygotes who show accelerated atrophy compared to APOE3/3 patients with Early AD. HV may be a marker of synaptic loss and neurodegeneration. |
Baseline to Week 78
|
|
Cortical Thickness (Whole Cortex) (MCI Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. |
Baseline to Week 78
|
|
Cortical Thickness (Whole Cortex) (Mild AD Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. |
Baseline to Week 78
|
|
Cortical Thickness (Mayo Index) (MCI Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex. |
Baseline to Week 78
|
|
Cortical Thickness (Mayo Index) (Mild AD Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) cortical thickness (mm) as measured by MRI. Brain MRI studies in Alzheimer's Disease patients show progressive cortical atrophy, reflecting progressive neurodegeneration. The Mayo Index refers specifically to the measurement of cortical thickness in the medial temporal lobe versus the whole cortex. |
Baseline to Week 78
|
|
Whole Brain Volume (MCI Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Whole Brain Volume (Mild AD Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in whole brain volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Ventricular Volume (MCI Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Ventricular Volume (Mild AD Subgroup)
Prazo: Baseline to Week 78
|
Change from baseline in total (bilateral) ventricular volume (uL) as measured by Magnetic Resonance Imaging (MRI). |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Female Subgroup of the FAS
Prazo: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Cognitive Efficacy Endpoint (ADAS-Cog 13) - Male Subgroup of the FAS
Prazo: Baseline to Week 78
|
Change from baseline in Alzheimer's Disease Assessment Scale - Cognitive Subscale 13 (ADAS-cog 13) scores at 78 weeks. The ADAS-Cog13 is a rater administered instrument that was designed to assess the severity of the dysfunction in the cognitive and noncognitive behaviors characteristic of persons with AD. The cognitive subscale of the ADAS-Cog13 consists of 13 items assessing areas of cognitive function most typically impaired in AD: orientation, verbal memory, language, praxis, delayed free recall, digit cancellation. The ADAS-Cog13 scale ranges from 0 to 85. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
A-IADL-W - Female Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
A-IADL-W - Male Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Amsterdam - Instrumental Activities of Daily Living scores calculated using the weighted average method (A-IADL-W score). The A-IADL Questionnaire is a 70-item informant-based computerized questionnaire aimed at detecting deficits in complex functions at the early stages of AD. Instrumental ADL can be described as the activities necessary to function independently in society. These activities include, but are not limited to, cooking, doing finances, and shopping. They are complex everyday tasks, determined by multiple cognitive processes and controlled processing. They can be distinguished from basic ADL, which include basic self-care skills. The A-IADL-W has a score range of 0-100 and is calculated as follows: (sum of all scores / number of questions scored) × 25. For A-IADL-W, higher scores indicates worse functioning or more impairment. |
Baseline to Week 78
|
|
CDR-SB - Female Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
CDR-SB - Male Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Clinical Dementia Rating - Sum of Boxes (CDR-SB) scores. CDR-SB is a semi-structured interview of participants and their caregivers. Participant's cognitive status is rated across 6 domains of functioning, including memory, orientation, judgment/problem solving, community affairs, home/hobbies, and personal care. Severity score assigned for each of 6 domains; Total score (SB) ranges from 0 to 18. Higher scores indicate greater disease severity. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - Female Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Functional Assessment (DAD) - Male Subgroup
Prazo: Baseline to Week 78
|
Change from baseline in Disability Assessment for Dementia (DAD)scores. The DAD consists of 40 items with a score range of 0-100 to evaluate the basic and instrumental activities of daily living of subjects with dementia. It is administered through an interview with the caregiver. Higher DAD scores indicate less disability or better function. |
Baseline to Week 78
|
|
Treatment Emergent Adverse Events (TEAE) - Females
Prazo: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group |
Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
|
Treatment Emergent Adverse Events (TEAE) - Males
Prazo: Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Safety and tolerability as measured by incidence of treatment emergent adverse events (TEAE), serious TEAEs, and TEAEs experienced by at least 5% of participants in either treatment group |
Entire study: approximately 82 weeks. (first dose of study drug until end of Safety Follow-up Visit at 28 +/- 7 days after the last dose (ie, 78-week treatment period plus 4-weeks follow-up after last dose up to total of 82 weeks)
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Colaboradores
Colaboradores
Investigadores
Investigadores
- Investigador principal: Susan Abushakra, MD, Alzheon Inc.
Publicações e links úteis
Publicações Gerais
- Hey JA, Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada M, Doraiswamy PM, Elahi FM, Rissman RA, Liang E, Flint S, Hristova E, Kesslak P, McLaine R, Albayrak A, Schaefer JF, Yu JY, Tolar L, Tolar M. Plasma Biomarker Effects of Oral Valiltramiprosate/ALZ-801 in Early Alzheimer's Disease from Phase 3 and Phase 2 Trials: Analysis of Core Biomarkers and Correlations with Clinical and Neuroimaging Outcomes. Drugs. 2026 Sep 1. doi: 10.1007/s40265-026-02381-3. Online ahead of print.
- Abushakra S, Power A, Watson D, Porsteinsson A, Sabbagh M, MacSweeney E, Cohen S, Boada Rovira M, Doraiswamy PM, Liang E, Flint S, Kesslak JP, McLaine R, Albayrak A, Schaefer J, Yu J, Tolar L, Dickson S, Hey JA, Tolar M. Clinical Efficacy, Safety and Imaging Effects of Oral Valiltramiprosate in APOEepsilon4/epsilon4 Homozygotes with Early Alzheimer's Disease: Results of the Phase III, Randomized, Double-Blind, Placebo-Controlled, 78-Week APOLLOE4 Trial. Drugs. 2025 Nov;85(11):1455-1472. doi: 10.1007/s40265-025-02250-5. Epub 2025 Sep 28.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- ALZ-801-AD301
- R01AG065253 (Concessão/Contrato do NIH dos EUA)
- 2020-005755-20 (Número EudraCT)
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .